---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-029078"
form_type: "8-K"
ticker: "ANVS"
cik: "0001477845"
company_name: "Annovis Bio, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:25:23.529005+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Annovis Bio restates 2022 interim financials due to R&D expense misclassification; expects material weakness

## Summary
- Material amounts of R&D expenses were misclassified as prepaid assets in Q1-Q3 2022 interim financials.
- Previously issued unaudited financials for March 31, June 30, and September 30, 2022 should no longer be relied upon.
- Company expects to report at least one material weakness in internal control over financial reporting.
- Restatements will be included in the 2022 Form 10-K; cash position for each period is not expected to change.
- Audit Committee and Board concluded restatement is appropriate after consulting with management and auditor WithumSmith+Brown.

## SEC filing metadata
- accession: 0001104659-23-029078
- form_type: 8-K
- ticker: ANVS
- cik: 0001477845
- company_name: Annovis Bio, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 4.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477845/000110465923029078/0001104659-23-029078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477845/000110465923029078/tm238624d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-029078
- JSON: https://secwatch.observer/filing/0001104659-23-029078.json
- Plain text: https://secwatch.observer/filing/0001104659-23-029078.txt

## Key facts
- Auditor Changes
  Annovis Bio, Inc. reported that prior financial statements should not be relied upon.
  - Action: non reliance
  source text: ear ended December 31, 2022 the restated financial statements for each of the Non-Reliance Periods (“Restatements”). As a result, the unaudited financial statements for each of the Non-Reliance Periods should no longer be relied on. S imilarly, any previously issued or filed reports, press releases, earnings releases, and investor presentations or other communications describing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477845/000110465923029078/0001104659-23-029078-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.